Everything that happens to a cell occurs as a result of “signals” that start or stop specific processes inside the cell. The signals tell the cell to grow, to make a new protein, or to become a different kind of cell. Whether it’s a brain, nerve, skin or bone cell, every process necessary to life only happens when signals are sent or received in the right way and at the right time. All the projects in my lab center on the study of those signals, an area we refer to as “signal transduction."
Signal transduction can be compared to an electric circuit, where wires from an on/off switch send power from its source to a device. The wiring diagram in a cell is very complicated and more like a stereo system. It will play tapes, CDs or radio; it will connect to your television or speakers, it will have volume, balance and tuning properties, and there are amplifiers and current regulators. We study what happens between the power source and the desired output—in this case, music. What specific thing is turned on with what switch, and how does it control the quality and quantity of the cellular music? That’s what we want to know.
One of our projects focuses on anthrax and why it kills people. Once anthrax is contracted, the on/off switch in blood cells should stimulate the circuit and activate the body’s bacteria fighters. But in anthrax, the on/off switch doesn’t work properly, so the bacteria continue to grow unchecked. This results in a sepsis-like condition, where the bacteria grow uncontrolled in the bloodstream. We are looking at how the cells respond to the bacteria and how to develop ways for them to fight it more effectively.
In a new project, we look at the reasons some vaccines work and some don’t. Vaccines introduce a small particle of a foreign substance into the body. Ideally, the body produces antibodies against the substance, which, in turn, provide immunity. But some people don’t respond to vaccines or are poorly protected, as often happens with the anthrax vaccine. In animals, we found many signaling proteins that control the music of vaccines. We think similar problems happen in people, too. By learning more about how vaccines signal the immune system, we may be able to predict which vaccines will work best and develop better, more targeted vaccines for anthrax and other diseases.
Our laboratory has three main projects, all of which study the signal transduction processes in hematopoietic cells. In the area of inflammation, we are studying the signal transduction process by receptors for gamma-type immunoglobulins on human macrophages and neutrophils. These IgG receptors stimulate many biological functions in these cells, including phagocytosis, release of inflammatory cytokines and the elimination of pathogenic organisms. We found that inflammatory cytokines, especially Interleukin-6 (IL-6), suppress development of B lymphocytes at a very early stage. Patients with elevated IL-6 have chronic inflammation, like that present in autoimmune diseases like rheumatoid arthritis. Likewise, elevated IL-6 is found in patients with lymphomas such as multiple myelomas and other plasmacytomas. We are identifying the individual proteins that signal cells to make IL-6.
We also study how B lymphocytes are activated by their antigen receptors. B lymphocytes respond to pathogenic proteins through surface immunoglobulin (sIg). Our work in signal transduction by sIg has shown recruitment of several proteins to the sIg receptor when it is stimulated by antigens. The enzyme phosphatidylinositol 3-kinase (PI3K) is central to protein recruitment since inhibiting PI3K blocks all aspects of B-cell activation. We use mice deficient in the enzymes that regulate PI3K to study the role of PI3K in B cells. Our current work focuses on how sIg-recruited proteins contribute to antigen internalization and B lymphocyte activation, with emphasis on the key role of PI3K.
The third project involves signal transduction by a receptor tyrosine kinase (c-fms) that triggers macrophage migration. We are studying how PI3K regulates small GTPases Rho, Rac and CDC42. Primary macrophages from the bone marrow of mice that have altered metabolism of PI3K products show elevated chemotactic responses. We have traced the elevation to constitutively-active Rac and Vav in these same macrophages. By retroviral transduction and fluorescence microscopy, we determined how Vav is regulated by PI3K products. Our future studies will examine how these proteins involved in the signal transduction process are able to regulate assembly of the actin cytoskeleton and movement of the cell.
B.S., Southern Illinois University, 1979
M.S., Southern Illinois University, 1981
Ph.D., Duke University, 1985
Honors and Awards
NIH Predoctoral Fellowship, Duke University Medical Center
1989-1991 Cancer Research Institute Fellowship
Recipient, Scholar of the Leukemia and Lymphoma Society
Panel member, NSF Signal Transduction & Regulation Panel Group
Panel member, NIH Immunobiology Study Section (T32s)
Ad Hoc Panel Member, NIH Allergy & Immunology (2/00): Experimental Immunology (6/00) Study Sections
Session Chair, B cell activation and development; Autumn Immunology Conference, Chicago, IL
Council Member, Autumn Immunology Conference (02-05)
Special Emphasis Panel: Biology of Dendriitic Cells; 2001
Special Emphasis Panel: Technology Centers for Networks and Pathways: 2005
Session Chair, Molecular events in B cell activation; AAI Conference, Seattle, WA
2014 Fred Jones Award for Scientific Achievement
Panel Member, AHA Immunology & Microbiology II.
Associate editor, Journal of Biological Chemistry
Associate editor, Journal of Immunology
American Society of Biochemists and Molecular Biologists
Joined OMRF Scientific Staff in 1999
Booth JL, Duggan ES, Patel VI, Wu W, Burian DM, Hutchings DC, White VL, Coggeshall KM, Dozmorov MG, Metcalf JP. Gene expression profiling of primary human type I alveolar epithelial cells exposed to Bacillus anthracis spores reveals induction of neutrophil and monocyte chemokines. Microb Pathog 121:9-21, 2018 August, PMID: 29704667, PMCID: PMC6077097
Girton AW, Popescu NI, Keshari RS, Burgett T, Lupu F, Coggeshall KM. Serum Amyloid P and IgG Exhibit Differential Capabilities in the Activation of the Innate Immune System in Response to Bacillus anthracis Peptidoglycan. Infect Immun 86, 2018 April, PMID: 29531132, PMCID: PMC5913848
Langer M, Girton AW, Popescu NI, Burgett T, Metcalf JP, Coggeshall KM. Neither Lys- and DAP-type peptidoglycans stimulate mouse or human innate immune cells via Toll-like receptor 2. PLoS One 13:e0193207, 2018 February, PMID: 29474374, PMCID: PMC5825070
Popescu NI, Silasi R, Keshari RS, Girton A, Burgett T, Zeerleder SS, Gruber A, Lupu F, Coggeshall KM. Peptidoglycan induces disseminated intravascular coagulopathy through activation of both coagulation pathways. Blood. 2018 132(8):849-860. PMID: 29921614 PMCID: PMC6107880
Sun D, Popescu NI, Raisley B, Keshari RS, Dale GL, Lupu F, Coggeshall KM. B. anthracis peptidoglycan activates human platelets through FcγRII and complement. Blood. 2013 Jul 25;122(4):571-9. PMID: 23733338 PMCID: PMC3724192
Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James JA, Farris AD, Kurosawa S. The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax. J Cell Mol Med. 2013 Jul;17(7):914-20. PMID: 23742651 PMCID: PMC3729634
Sun D, Raisley B, Langer M, Iyer JK, Vedham V, Ballard JL, James JA, Metcalf JP, Coggeshall KM. 2012. Anti-peptidoglycan antibodies and Fcγ receptors are the key mediators of inflammation in gram-positive sepsis. J Immunol. 2012 Sep 1;189(5):2423-31. PMID: 22815288 PMCID: PMC3424298
Iyer JK, Coggeshall KM. Cutting edge: primary innate immune cells respond efficiently to polymeric peptidoglycan, but not to peptidoglycan monomers. J Immunol. 2011 Apr 1;186(7):3841-5. PMID: 21357534 PMCID: PMC3071148
Iyer JK, Khurana T, Langer M, West CM, Ballard JD, Metcalf JP, Merkel TJ, Coggeshall KM. Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect. Immun., 78:2418-2428, 2010. PMID: 20308305 PMCID: PMC2876538
Arthritis & Clinical Immunology Research Program, MS 53
Oklahoma Medical Research Foundation
825 N.E. 13th Street
Oklahoma City, OK 73104
Phone: (405) 271-7905
Lab: (405) 271-7883
Fax: (405) 271-8568
News from the Coggeshall lab
As a resurgent H1N1 flu virus worries medical professionals and families, more people are looking to vaccines to keep them safe. Now a new discovery by scientists at OMRF could shed light on why vaccines are ineffective in some patients. In a paper published in the current issue of the Journal of Biological Chemistry, OMRF researchers Shikha […]
The National Institutes of Health has awarded two grants worth a total of $26.3 million to OMRF for research into anthrax and to help train new scientists. Each grant will allow scientists to continue research started in 2004 and 2005 and keep them working through 2014 on several interconnected projects. In the first project, a $14.5 […]
The National Institutes of Health has awarded the Oklahoma Medical Research Foundation a $9.16 million grant to train junior scientists and build research infrastructure at OMRF. The five-year award will fund the work of five junior scientists and provide operating support for core facilities at the foundation. “This is yet another important step in the […]
The National Institutes of Health has awarded the Oklahoma Medical Research Foundation $8.132 million to study the influenza vaccine. The five-year project will examine why the vaccine does not protect certain individuals with compromised immune systems.”Influenza research is one of the most competitive and difficult arenas in which to secure funding,” said J. Donald Capra, […]
The Oklahoma Medical Research Foundation has received a $13.8 million grant from the National Institutes of Health to study the toxin that causes anthrax. The grant will pay $2.76 million a year through 2009 and is the largest ever awarded to an Oklahoma institution to fund bioterrorism research.With this grant, nine scientists will explore natural […]
Oklahoma City, April 23, 2003 – At its semiannual board meeting last night, the Oklahoma Medical Research Foundation presented the Edward L. and Thelma Gaylord Prize for Scientific Achievement to OMRF scientist Paul W. Kincade, Ph.D. Also Tuesday, OMRF honored longtime director H.E. “Gene” Rainbolt, named K. Mark Coggeshall, Ph.D., as the first holder of […]
For the second time in 13 months, a substantial gift from the Kerr Foundation has created a new endowed chair at the Oklahoma Medical Research Foundation. The most recent donation will establish the Lou C. Kerr Endowed Chair in Biomedical Research. Robert S. Kerr Jr. made the gift on behalf of the Kerr Foundation in […]